Collaborative Stage Coding Prostate Cases

Similar documents
Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Prostate Case Scenario 1

Boot Camp Case Scenarios

Bladder Case # 1. Principal Diagnosis: Bladder Tumor, Suspect Transitional Cell Carcinoma. Secondary Diagnoses: 1. Hypertension. 2. Hyperlipidemia.

Prostate Overview Quiz

THE UROLOGY GROUP

A schematic of the rectal probe in contact with the prostate is show in this diagram.

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Collaborative Staging

da Vinci Prostatectomy

SEER Summary Stage Still Here!

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Head & Neck Case # 1

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Case Scenario 1: Breast

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

INGUINAL HERNIA REPAIR PROCEDURE GUIDE

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

DISCHARGE DIAGNOSES: End stage renal disease secondary to rapidly progressive glomerulonephritis.

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009

Exercise. Discharge Summary

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER

Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

11/21/13 CEA: 1.7 WNL

Case Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma

David Gillatt Bristol Urological Institute. David Gillatt Bristol UK

Case Scenario 1: Thyroid

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).

Chapter 18: Glossary

Kidney Case # 1 DISCHARGE SUMMARY. Date: 08/25/2010. Admitted: 08/19/2010 Discharged: 08/25/2010

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy

Prostate Cancer. Diagnosis and Treatment. September 2016 Saskatchewan Prostate Assessment Pathway

Compliance Department ELEMENTS OF GENITOURINARY EXAMINATION 11/2010

Kidney Case 1 SURGICAL PATHOLOGY REPORT

Citation Acta medica Nagasakiensia. 1963, 8(

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Patient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

Prostate Cancer. David Wilkinson MD Gulfshore Urology

In some cases, a medical evaluation may be needed, to be performed by your primary care physician about 2-4 weeks prior to surgery.

GUIDELINES ON PROSTATE CANCER

RECTAL INJURY IN UROLOGIC SURGERY. Inadvertent rectal injury from a urologic procedure is often subtle but has serious postoperative consequences.

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Merkel Cell Carcinoma Case # 2

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Breast conservation surgery and sentinal node biopsy: Dr R Botha Moderator: Dr E Osman

Gross Anatomy of the Urinary System

Melanoma Case Scenario 1

Department of Urology, Cochin hospital Paris Descartes University

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

Melanoma Case Scenario 1

Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:

LIVING WITH. Understanding Your Treatment Options 1510

Clinical Study Retrograde Robotic Radical Prostatectomy: Description of a New Technique and Early Perioperative Outcomes

Lecture 56 Kidney and Urinary System

Chapter 2. Understanding My Diagnosis

Inferior Pelvic Border

Prostate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)

Citation for published version (APA): Haber, G. P. (2010). Application of emerging technologies to urologic oncology

PROSTATE CANCER: A Primer of Diagnosis and Treatment. Jay C. Lee, MD, FRCSC Clinical Associate Professor University of Calgary

This information is intended as an overview only

DISSECTION 8: URINARY AND REPRODUCTIVE SYSTEMS

AllinaHealthSystems 1

Robot Assisted Laparoscopic Radical Prostatectomy

Case Study Review #2!

Robot Assisted Radical Prostatectomy

General information about prostate cancer

Neoplasms of the Prostate and Bladder

PROSTATE CANCER CONTENT CREATED BY. Learn more at

BRACHYTHERAPY FOR PROSTATE CANCER. Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Case Scenario 1. History

QUESTIONS TO ASK A UROLOGIST

Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends

Penis Cancer. What is penis cancer? Symptoms. Patient Information. Pagina 1 / 9. Patient Information - Penis Cancer

Robotic Surgery for Prostate Cancer: A Realistic Approach to Getting Started The Evolution of a Robotic Surgeon

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

Case Scenario 1. Discharge Summary

Definition of Synoptic Reporting

A215- Urinary bladder cancer tissues

Robotic-assisted right inferior lobectomy

Robotics, Laparoscopy & Endosurgery

Prostate Cancer. What is prostate cancer?

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

LDR prostate brachytherapy

Genitourinary. Presentation Outline. Genitourinary System 12/14/2011. FCDS 2011 Educational Webcast Series December 15, 2011

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Transcription:

PROSTATE CASE 1 History & Physical 7/2 The patient is a 63 year old male with normal physical exam. Digital rectal exam showed normal seminal vesicles. Prostate smooth with no palpable nodules. Biopsy performed for elevated PSA. Imaging 7/12 Chest x-ray within normal limits. 7/15 CT Scan of abdomen and pelvis showed no metastatic disease. Laboratory 6/23 PSA elevated at 14.6 Procedures 7/2 TRUS biopsy of the prostate Pathology Report 7/2 Left mid region: adenocarcinoma, poorly differentiated. Gleason s score 5 (3+2). Right side negative. Treatment: 7/16 Patient opted for interstitial prostatic seed implants which were performed as an outpatient. Answer Worksheet Primary Site C. Reg LN Pos Histology/Behavior and Grade / Reg LN Exam CS Tumor Size CS Mets at Dx CS Extension CS Mets Eval CS TS/Ext Eval CS SSF 1 CS Lymph Nodes CS SSF 2 CS Reg Nodes Eval CS SSF 3 1

PROSTATE CASE 2 Physical Examination 11/8 Patient is a 56-year-old male seen for annual physical exam and had an incidental PSA elevation of 6.0. Prostate was smooth with no abnormalities. All other systems were normal. Laboratory 11/5 PSA elevated at 6.0 Procedures 11/8 Sextant biopsy of the prostate 11/25 Radical prostatectomy: Excised prostate including capsule, pelvic lymph node dissection, seminal vesicles, and small portion of bladder neck. Pathology 11/8 Prostate biopsy: Right lobe, negative. Left lobe, small focus of adenocarcinoma, Gleason s 4 + 3 in approximately 5% of the tissue. 11/25 Radical prostatectomy: Prostate gland showing moderately differentiated infiltrating adenocarcinoma, Gleason 3 + 2. Tumor involved both lobes of the prostate with extracapsular extension on the right side only. Surgical margins involved on the right. The seminal vesicles were free. Apex is uninvolved. All lymph nodes examined were negative. Discharge Note Patient has made good post-op recovery other than mild urgency incontinence. His post-op PSA is 0.1 mg/ml. Answer Worksheet Primary Site C. Reg LN Pos Histology/Behavior and Grade / Reg LN Exam CS Tumor Size CS Mets at Dx CS Extension CS Mets Eval CS TS/Ext Eval CS SSF 1 CS Lymph Nodes CS SSF 2 CS Reg Nodes Eval CS SSF 3 2

PROSTATE CASE 3 DISCHARGE SUMMARY Date of Admission: 04/26/20xx Date of Discharge: 04/30/20xx Admission Diagnosis: Prostate cancer. Discharge Diagnosis: Prostate cancer. Procedure: Robotic-Assisted Laparoscopic Prostatectomy. Present Medical History: This is a 61 year old male who was found to have a PSA of 4.5 and a free PSA of 12.7 who underwent a transrectal ultrasound biopsy which revealed prostate cancer, 3+3, at the right base with perineural invasion. At the right mid, he had a Gleason 1+2=3 and at the left base, he had a Gleason 2+3=5. The patient was without any incontinence or erectile problems preoperatively. He was consented for the aforementioned procedure and underwent this on 04/26/20xx. Hospital Course: Postoperatively, the patient did well. On postoperative days # 1 and # 2, he did develop a probable urethra-vesicle leak with a large amount of urine being taken out by his pelvic Jackson-Pratt drain. On postoperative day # 3, his Jackson-Pratt drain had been placed to gravity. The drainage had decreased over the 12 hour period prior to discharge. His Jackson-Pratt drain had been placed back on suction with no increased Jackson-Pratt drain output. The patient was tolerating p.o., ambulatory, having normal bowel movements, pain well controlled with p.o. pain medication and all vital signs were stable. Disposition: He will be discharged to home with follow-up with Dr. XX at the end of next week. He will be discharged to home with the Foley catheter to a leg bag. He has been instructed to call XX Clinic Foundation for any questions or concerns that he may have. HISTORY AND PHYSICAL Date: 01/24/20xx Present Medical History: This is a 61-year-old male who was found to have a PSA of 4.5, a free PSA of 12.7%. He had a transrectal ultrasound biopsy which revealed prostate cancer of 3 + 3 at the right base with perineural invasion. At the right mid, he had Gleason 1 + 2 = 3. At the left base, he had a Gleason 2 + 3. He has no voiding symptoms. He has no hesitancy, frequency, nocturia. No incontinence. He does not use any phosphodiesterase inhibitors. Past Medical History: Negative. Review of the systems: Negative for fever, weight loss, or malaise Physical Exam: General Appearance: he is in no apparent distress. Abdomen: mildly obese, soft, nontender, nondistended liver and spleen; no hepatosplenomegaly or hernia noted. Scrotum, epididymis, testicles, urethral meatus, and penis are normal. Prostate is smooth, symmetrical, nontender and non-nodular; seminal vesicles negative. Sphincter tone normal. DRE normal. Neck: no JVD. Respiratory: within normal limits. Cardiovascular: symmetrical femoral pulses. Lympatics: no inguinal lymphadenopathy. Skin: No rashes. Neurologic: Motor, sensory, orientation, mood and affect are all normal. 3

CONSULTATION REPORT Date: 01/24/20xx Reason: Second opinion of prostate cancer. PROSTATE CASE 3 Impression and Plan: Clinically looks like adenocarcinoma of the prostate. I had a long discussion with the patient regarding watchful waiting, hormonal therapy, cryotherapy, external beam radiation, brachytherapy, laparoscopic radical prostatectomy and open prostatetomy. He prefers to go with the robotic prostatectomy, and we will go ahead and get him scheduled. RADIATION REPORT Chest PA & Lateral Date 03/03/20xx Clinical History: Edema Findings: Heart size and pulmonary vascularity are within normal limits. Thoracic aorta is with calcification in the wall of the aortic arch. No hilar or mediastinal enlargement. The lungs are well expanded and appear free of active disease. No pleural fluid or pneumothorax. Hypertrophic degenerative changes involving the thoracic spine. Impression: no acute cardiopulmonary disease. 4

PROSTATE CASE 3 OPERATIVE REPORT Date: 04/26/20xx Preoperative Diagnosis: Clinical stage T1c adenocarcinoma of the prostate Postoperative Diagnosis: Clinical stage T1c adenocarcinoma of the prostate Operation Performed: Robotic-assisted laparoscopic radical prostatectomy Indications for procedure: Clinically localized adenocarcinoma of the prostate Procedure in Detail: After informed consent was obtained, the patient was taken to the operating room and placed in the supine position on the operating table. General endotracheal anesthesia was administered. The patient s legs were then placed in spreader bars and the table was properly positioned for robot prostatectomy. By doing so the patient was placed in steep Trendelenburg. The abdomen, penis and scrotum were then prepped and draped in sterile fashion. Foley catheter and orogastric tubes were placed. The Veress needle access was obtained to the peritoneal cavity and once proper placement was confirmed with the drop test, the abdomen was insufflated to 15 mmhg with CO2 gas. Once adequate pneumoperitoneum was obtained, a 10-2 trocar was placed through the incision just above the umbilicus. Additional trocars for the robot and instruments were placed lateral to the rectus muscle below the umbilicus in the left lower quadrant, and a 10-12 trocar was also placed in the right lower quadrant for assistant retraction as well as a 5 mm trocar in the right upper quadrant. These trocars were placed under direct vision using the Da Vinci camera. The Da Vinci robot was then docked to the trocars and secured to the patient. We then began dissection of the seminal vesicles and vas deferens. The vas deferens was transected and a piece of it was used as a bolster for the anastomosis. Seminal vesicles were also dissected. We then turned our attention to the tissue lateral to the medial umbilical ligaments on both sides. This allowed us to completely mobilize the bladder and drop it off the lower anterior abdominal wall. We then dissected the pubic bone to expose the anterior surface of the prostate and the endopelvic fascia. The retropubic fat was stripped off the prostate down to the bladder neck. We incised the endopelvic fascia with electrocautery and dissected more laterally as well as anteriorly to expose the lateral edges of the prostate. We took down the puboprostatic ligaments to expose the dorsal venous complex. The dorsal venous complex was then controlled with an Endo-GIA stapling device. Attention was then turned to the bladder neck. The bladder neck was then incised with the electrocautery at the base of the prostate. This was performed on both sides leaving the midline intact. We then dissected down to the bladder neck and used blunt dissection and electrocautery to preserve the bladder neck tissue. The proximal urethra was then divided with electrocautery and the posterior urethra was divided as well. We then dissected the posterior surface of the bladder off the base of the prostate. Once this was accomplished, Denonvilliers fascia was exposed. We then brought up the vas deferens and the seminal vesicles into the field. We elevated the seminal vesicles with the 4th arm of the robot in order to gain exposure to the pedicle dissection. We incised the posterior layer of Denonvilliers fascia to sweep the rectum down off the posterior surface of the prostate. This demonstrated the pedicles nicely. We then took the lateral pedicles of the prostate using a combination of bipolar cautery and monopolar cautery. Both neurovascular bundles were preserved on both sides. We then incised the lateral pelvic fascia to sweep the neurovascular bundles off the prostate and continued dissection inferiorly toward the apex of the prostate on both sides. Again, we were able to preserve both neurovascular bundles. Once this was accomplished, the prostate was pulled posteriorly towards the head of the patient to expose the dorsal venous complex and dorsal urethra. We then transected the urethra using electrocautery. We also were able to sweep the neurovascular bundles off of the apex of the prostate and lateral surface of the urethra to ensure preservation of the structures. The posterior urethra was then divided with electrocautery. After dividing the posterior urethra, we divided the rectourethralis muscle and then completely mobilized the prostate off the rectum to create the prostate. The pelvis was irrigated with saline and a JP drain was placed in the right lower quadrant, thus the urethral anastomosis was then performed using double armed suture of 2-0 Vicryl and 2-0 Monocryl of this sutured bolster of our vas bolster for initial suture. Once the anastomosis was completed, the Foley catheter was placed per urethra without difficulty. The bladder was irrigated. There was no evidence of leakage. The bladder irrigated well. We then placed the 5

OPERATIVE REPORT, continued PROSTATE CASE 3 prostate into an entrapment sac. The robot was undocked and the trocars were removed under direct vision. We then removed the prostate back staying in the midline trocar for a short distance. There was excellent hemostasis prior to removing the specimen. We then closed the extraction incision with interrupted sutures of 0 Vicryl. All wounds were irrigated and infiltrated with 0.25% Marcaine plain. The trocar sites were closed with Dermabond in the skin and the extraction site was closed with 4-0 Monocryl subcuticular suture. Steri- Strips were applied to the wound as well. The patient tolerated the procedure well. There were no intraoperative complications. He was reversed from anesthesia and taken to recovery room in good condition. PATHOLOGY REPORT Date: 04/26/20xx Specimen: Prostate and Vas Deferens. Gross and Microscopic Diagnosis: Radical Prostatectomy Specimen: Large total volume of adenocarcinoma, total Gleason score 6, with involvement of the apical margin, with no involvement of the right seminal vesicle identified. Gross: Received in formalin is a 35 gm, 4 x 3 x 3 cm prostate with attached vas and attached right seminal vesicle. The right seminal vesicle measures 3 cm in length and 1 cm in diameter. The right vas measures 3 cm in length and 0.5 cm in diameter. The left vas measures 4 cm in length and 0.5 cm in diameter. The prostate parenchyma has multiple ill-defined, firm, white to pink areas. The remainder parenchyma is spongy, filled with milky material. Margins are inked with black. Microscopic: Although there are large areas of prostate without neoplasia, there is a large total volume of carcinoma present. Carcinoma involves all regions of the prostate, although it is not identified in the right seminal vesicle. The carcinoma consists of glands, some of which have a smaller-than usual caliber, but with considerable variation in glandular size. These glands erratically infiltrate without a well defined periphery. Gleason 3+3. No extraprostatic extension is identified. Stage: pt2c pnx pmx. Addendum issued on 05/05/20xx: This case has been reviewed again. Carcinoma extends to the margin in several foci at the apex. At the apex there are benign glands extending into skeletal muscle. On the other hand, the carcinoma extends deeper into the skeletal muscle than the benign glands. The carcinoma also extends to some modest sized vascular and neural structures. It is my interpretation that the prudent case is to consider the carcinoma to have extracapsular extension into the apex. This interpretation leads to the pathologic stage of pt3a pnx pmx. 6

FIELD# FIELD NAME CODE RATIONALE/DOCUMENTATION 1 Patient Name Prostate Case #3 CANCER IDENTIFICATION 2 Primary Site 3 Histology 4 Behavior 5 Grade 6 Grade Path System 7 Grade Path Value 8 Lymph vascular invasion STAGE OF DISEASE AT DIAGNOSIS 9 CS Mets at Dx Bone 10 CS Mets at Dx Lung 11 CS Mets at Dx Liver 12 CS Mets at DX Brain COLLABORATIVE STAGING 13 CS Tumor Size 14 CS Extension 15 CS Tumor Size/Ext Eval 16 CS Lymph Nodes 17 CS Lymph Nodes Eval 18 Regional Nodes Positive 19 Regional Nodes Examined 20 CS Mets at Dx 21 CS Mets Eval 22 CS Site Specific Factor 1 23 CS Site Specific Factor 2 24 CS Site Specific Factor 3 25 CS Site Specific Factor 4 26 CS Site Specific Factor 5 27 CS Site Specific Factor 6 28 CS Site Specific Factor 7 29 CS Site Specific Factor 8 30 CS Site Specific Factor 9 31 CS Site Specific Factor 10 32 CS Site Specific Factor 11 33 CS Site Specific Factor 12 34 CS Site Specific Factor 13 35 CS Site Specific Factor 14 36 CS Site Specific Factor 15 37 CS Site Specific Factor 16 25 7

PROSTATE CASE 4 HISTORY AND PHYSICAL Date: 08/01/20xx Present Medical History: Mr. XX is 50 years old who has a history of an elevated PSA of 5.9, underwent transrectal ultrasound prostate biopsy by Dr. XX and was found to have Gleason 6 (3+3) adenocarcinoma of the prostate in the left base, left mid gland, right base and right apex. His clinical stage is T1c. Digital rectal exam reveals a 25 gm prostate, on transrectal ultrasound his prostate is 18 gm. He has no erectile dysfunction and no incontinence. He had a bone scan and a CT scan for metastatic workup all of which were negative. He denies any bone pain, weight loss, nausea, vomiting. No fever or chills. Past Medical History: Anxiety, osteoarthritis and depression. He has had some oral surgery. Social History: Negative for tobacco, IV drug use or alcohol. Physical Exam: Abdomen: benign, no palpable mass in liver or spleen; no hernias in the groin Anus/Perineum: normal Digital Rectal Exam: no nodules in the rectal vault; he has normal sphincter tone Scrotum: normal Epididymis: normal Testes: no masses Penis: circumcised, no lesions were present Urethral Meatus: normal Neck: nontender Respiratory: unlabored Lungs: clear to auscultation bilaterally Cardiovascular: no cyanosis, clubbing or edema in the extremities Lymphatic: no nodes palpable in the groin or in the neck Skin: warm without rashes. Neurologic: alert and oriented x 3, in no acute distress Urinalysis: today shows ph of 6 CONSULTATION REPORT Date: 08/01/20xx Reason: Prostate cancer. I would like to thank Mr. XX for the courtesy of this consult. I had a long discussion with the patient and his wife. I spent a total of 60 minutes with the patient and his wife discussing the treatment options of prostate cancer. I spent over 40 minutes in counseling. We discussed observation, hormonal therapy, cryotherapy, radiation therapy and surgery. The patient was specifically referred to me to consider robotic prostatectomy. We spent majority of our time discussing. We discussed the risks and benefits of surgery, which would include infection, bleeding, incontinence and erectile dysfunction. I also discussed with him the potential cancer cure rates based on the available literature. He had many questions all of which are believe are answered satisfactorily. We also discussed the excepted operative and postoperative course. Impression: Prostate cancer (clinical T1c, Nx, M0). 8

RADIOLOGY REPORT # 1 Date: 07/10/20xx Bone Scan PROSTATE CASE 4 Findings: There is no evidence of uptake most suggesting metastatic disease. There is arthritic type uptake involving the shoulders and knees. There is also mild increased uptake along the left aspect of the cervical spine probably related to degenerative changes. Kidneys are visualized with excretion to bladder. Impression: No evidence of uptake most suggestive of metastatic disease. RADIOLOGY REPORT # 2 Date: 07/10/20xx CT of the abdomen with and without IV contrast; CT of the pelvis with IV contrast Findings: The liver, spleen, pancreas, adrenal glands, and kidneys are unremarkable. There is no adenopathy or free fluid within the abdomen. There is no bowel wall thickening or bowel dilatation within the abdomen. CT of the pelvis demonstrates prostate gland mildly impressing on the bladder base with no obvious invasion. There is no adenopathy or free fluid within the pelvis. There is not bladder wall thickening. Impression: Prostate gland is mildly impressing on the bladder base with no obvious invasion. No evidence of any distant metastatic disease. PATHOLOGY REPORT # 1 Date: 07/24/20xx Specimen: Outside slides collected on 06/25/20xx Diagnosis: Biopsies of the left base, left mid, right base, and right apex of the prostate - Adenocarcinoma (Total Gleason score 6). Biopsies from the left apex and right mid - no definitive carcinoma identified. Microscopic: Adenocarcinoma involves 2 of 8 cores from the left base, 1 of 5 cores from the left mid, 4 of 10 cores from the right base, and 1 of 10 cores from the right apex. The carcinoma consists of basophilic glands with a smaller than usual caliber erratically infiltrating without a well defined periphery (Gleason grade 3). As there is only a single Gleason grade, the total score is 6. No definitive carcinoma is identified in the other portions of this case. 9

FIELD# FIELD NAME CODE RATIONALE/DOCUMENTATION 1 Patient Name Prostate Case #4 CANCER IDENTIFICATION 2 Primary Site 3 Histology 4 Behavior 5 Grade 6 Grade Path System 7 Grade Path Value 8 Lymph vascular invasion STAGE OF DISEASE AT DIAGNOSIS 9 CS Mets at Dx Bone 10 CS Mets at Dx Lung 11 CS Mets at Dx Liver 12 CS Mets at DX Brain COLLABORATIVE STAGING 13 CS Tumor Size 14 CS Extension 15 CS Tumor Size/Ext Eval 16 CS Lymph Nodes 17 CS Lymph Nodes Eval 18 Regional Nodes Positive 19 Regional Nodes Examined 20 CS Mets at Dx 21 CS Mets Eval 22 CS Site Specific Factor 1 23 CS Site Specific Factor 2 24 CS Site Specific Factor 3 25 CS Site Specific Factor 4 26 CS Site Specific Factor 5 27 CS Site Specific Factor 6 28 CS Site Specific Factor 7 29 CS Site Specific Factor 8 30 CS Site Specific Factor 9 31 CS Site Specific Factor 10 32 CS Site Specific Factor 11 33 CS Site Specific Factor 12 34 CS Site Specific Factor 13 35 CS Site Specific Factor 14 36 CS Site Specific Factor 15 37 CS Site Specific Factor 16 25 10